Lars Grönke

Tiotropium and olodaterol fixed-dose combination <i>versus</i> mono-components in COPD (GOLD 2–4)

Roland Buhl, François Maltais, R Abrahams et al. · European Respiratory Journal · 2015 · 322 citations · Full text

Pharmacy, Clinical Sciences, Pharmacotherapy +17

Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial

Peter M.A. Calverley, Antonio Anzueto, Kerstine Carter et al. · The Lancet Respiratory Medicine · 2018 · 198 citations · Full text

Medicine, Pharmacotherapy, Preventive Medicine +9

Tiotropium + olodaterol shows clinically meaningful improvements in quality of life

Dave Singh, Gary T. Ferguson, J Bolitschek et al. · Respiratory Medicine · 2015 · 175 citations · Full text

Pharmacy, Clinical Sciences, Pharmacotherapy +17

The 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease

Kai-Michael Beeh, Jan Westerman, Anne‐Marie Kirsten et al. · Pulmonary Pharmacology & Therapeutics · 2015 · 113 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

The lung function profile of once-daily tiotropium and olodaterol via Respimat&amp;reg; is superior to that of twice-daily salmeterol and luticasone propionate via&amp;nbsp;Accuhaler&amp;reg; (ENERGITO&amp;reg; study)

Kai Michael Beeh, Eric Derom, José Echave-Sustaeta et al. · International Journal of COPD · 2016 · 106 citations · Full text

Pharmacy, Pharmacotherapy, Comparative Effectiveness Research +16